Document Detail


Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
MedLine Citation:
PMID:  15188945     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Studies suggest that endothelin-1 contributes to the pathogenesis of hypertension. A G5665T gene polymorphism of preproendothelin-1 has been shown to be associated with higher blood pressure in overweight patients. No study has yet determined the effect of this polymorphism on the change in blood pressure during antihypertensive treatment. HYPOTHESIS: This study aimed to determine this effect in hypertensive patients with left ventricular (LV) hypertrophy during antihypertensive treatment with either irbesartan or atenolol. METHODS: We determined the preproendothelin-1 genotype using minisequencing in 102 patients with essential hypertension and LV hypertrophy verified by echocardiography, randomized in a double-blind fashion to treatment with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol. RESULTS: The change in systolic blood pressure (SBP) after 12 weeks of treatment was related to the preproendothelin-1 genotype in men; after adjustment for potential covariates (age, blood pressure, and LV mass index at study entry, dose of irbesartan/atenolol, and type of treatment), those carrying the T-allele responded on average with a more than two-fold greater reduction than those with the G/G genotype (-21.9 mmHg 13.9] vs. -8.9 [2.3], p = 0.007). No significant differences in blood pressure change between G/G and carriers of the T-allele were seen among women. CONCLUSIONS: Our finding suggests a gender-specific relationship between the G5665T preproendothelin-1 polymorphism and change in SBP in response to antihypertensive treatment with irbesartan or atenolol, suggesting the endothelin pathway to be a common mechanism included in the hypertensive action of the drugs.
Authors:
P Hallberg; J Karlsson; L Lind; K Michaëlsson; L Kurland; T Kahan; K Malmqvist; K P Ohman; F Nyström; U Liljedahl; A C Syvänen; H Melhus
Related Documents :
18855255 - Sexual dimorphism on hypertension of quantitative trait loci entrapped in dahl congenic...
17698725 - Selective genotyping reveals association between the epithelial sodium channel gamma-su...
19444285 - Arg347cys polymorphism of alpha1a-adrenoceptor gene is associated with blood pressure r...
16685205 - Functional variants of the angiotensinogen gene determine antihypertensive responses to...
2734355 - Characterization of stress reactions to the stroop color word test.
1324015 - A novel platelet-derived renal vasoconstrictor agent in normotensives and essential hyp...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical cardiology     Volume:  27     ISSN:  0160-9289     ISO Abbreviation:  Clin Cardiol     Publication Date:  2004 May 
Date Detail:
Created Date:  2004-06-10     Completed Date:  2004-10-14     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7903272     Medline TA:  Clin Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  287-90     Citation Subset:  IM    
Affiliation:
Department of Medical Sciences, Uppsala University, Uppsala, Sweden. par.hallberg@medsci.uu.se
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / pharmacology*,  therapeutic use
Atenolol / pharmacology*,  therapeutic use
Biphenyl Compounds / pharmacology*,  therapeutic use
Blood Pressure / drug effects*,  genetics*
Endothelin-1 / genetics*
Female
Genotype
Humans
Hypertension / complications,  drug therapy,  genetics
Hypertrophy, Left Ventricular / complications,  drug therapy,  genetics
Male
Middle Aged
Polymorphism, Genetic
Sex Factors
Tetrazoles / pharmacology*,  therapeutic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Endothelin-1; 0/Tetrazoles; 138402-11-6/irbesartan; 29122-68-7/Atenolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Plasma vascular endothelial growth factor level is elevated in patients with multivessel coronary ar...
Next Document:  The importance of gender on coronary artery size: in-vivo assessment by intravascular ultrasound.